

## Starpharma to present DEP<sup>®</sup> at US Drug Delivery Conference

**Melbourne, Australia; 28 October 2021:** Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it has been invited to present at the 11<sup>th</sup> annual Partnership Opportunities in Drug Delivery (PODD) conference, which will take place virtually this year on 28-29 October 2021.

PODD brings together leaders in the Pharmaceutical Industry's product development, R&D and drug delivery experts to discuss industry needs and latest trends. The conference also showcases innovative drug delivery technologies which could improve the delivery of pharmaceuticals.

The PODD conference includes expert speakers and attendees from leading pharmaceutical companies including AstraZeneca, Pfizer, Roche Pharma, Novartis, Genentech, Merck, and Sanofi. PODD also provides an excellent opportunity for business development activities through organised networking and a partnering tool for new, emerging, and established collaborations.

Starpharma will be represented by its VP of Business Development, Tony Eglezos, who will present an overview of the DEP<sup>®</sup> platform and its benefits as part of the 'Injectable Formulation Technologies' stream. Starpharma's presentation "Enhancing drug delivery: DEP<sup>®</sup> dendrimer platform" is scheduled at 2:00pm (US Eastern Time) 28 October 2021, and includes:

- Overview of Starpharma's DEP<sup>®</sup> strategy, and how the Company is leveraging its proprietary dendrimer platform to build high value products and partnerships that address significant unmet need
- Therapeutic and commercial benefits of the DEP<sup>®</sup> drug delivery platform in oncology and other therapeutic areas, including in combination therapies and new technology
- Overview of Starpharma's three internally developed phase 2 clinical programs
- Use of DEP<sup>®</sup> in the development of Antibody Drug Conjugates (ADCs), including the ability to provide additional flexibility in targeting
- Use of DEP<sup>®</sup> in the development of radiodiagnostic and radiotherapeutic conjugates, and the potential benefits of minimising off target toxicity and enhancing efficacy
- Broad applicability therapeutic and commercial benefits of Starpharma's DEP<sup>®</sup> platform

Starpharma will also be conducting partnering discussions with other pharmaceutical companies attending the conference.

A copy of the presentation will be made available on Starpharma's website at [www.starpharma.com](http://www.starpharma.com).

---

### About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for respiratory viruses, DEP<sup>®</sup> drug delivery and VivaGel<sup>®</sup>. Starpharma has developed VIRALEZE<sup>™</sup>, an antiviral nasal spray that is registered for sale in the UK/Europe and India, and available in certain markets online. VIRALEZE<sup>™</sup> is not approved for sale or supply in Australia. SPL7013 is utilised in approved products - the VivaGel<sup>®</sup> condom and VivaGel<sup>®</sup> BV. VivaGel<sup>®</sup> BV has been licensed in >160 countries, is registered in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, South Africa, Australia and New Zealand.



As a leading company in dendrimer-based drug delivery, Starpharma's proprietary drug delivery platform technology, DEP<sup>®</sup>, is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP<sup>®</sup> versions of existing drugs, particularly in the area of anti-cancer therapies. DEP<sup>®</sup> partnerships include oncology programs with AstraZeneca, with Merck in the area of Antibody Drug Conjugates (ADCs), with Chase Sun in the area of anti-infectives and other world leading pharmaceutical companies. Starpharma's partnered DEP<sup>®</sup> programs have the potential to generate significant future milestones and royalties.

[Starpharma.com](http://Starpharma.com) | [Twitter](#) | [LinkedIn](#)

---

**Media: Sumit Media**

Grant Titmus  
Mob: +61 419 388 161  
[grant@sumitmedia.com.au](mailto:grant@sumitmedia.com.au)

**Starpharma Holdings Limited**

Dr Jackie Fairley, Chief Executive Officer  
Nigel Baade, CFO and Company Secretary  
+61 3 8532 2704  
[investor.relations@starpharma.com](mailto:investor.relations@starpharma.com)  
4-6 Southampton Crescent  
Abbotsford Vic 3067

**Disclosure**

This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.

**Forward Looking Statements**

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.